James B. Koprich, MA, PhD, is chief scientific officer at Atuka Inc.; a scientific associate at Toronto Western Hospital, University Health Network; and visiting professor of neurology at Huashan Hospital, Fudan University. His research in Parkinson’s disease has largely focused on development and characterization of disease models and on pre-clinical evaluation of novel therapeutics for disease modification and reduction of dyskinesia. Dr. Koprich has conducted a number of studies contributing to the understanding of disease pathogenesis.
Associated Grants
-
Studies to Assess the Potential of Gold “Nanocrystals” for the Treatment of Parkinson’s Disease
2021
-
-
The Effects of a LRRK2 Inhibitor on Alpha-synuclein-induced Dopamine Deficits in a Pre-clinical Model of Parkinson's Disease
2017
-
Characterization, Optimization and Validation of a Preformed Fibril Pre-clinical Model of Parkinson's Disease
2016